Quality-adjusted time without symptoms of disease progression or toxicity of treatment (Q-TWiST) analysis to assess benefit-risk of sacituzumab govitecan (SG) in previously treated patients (pts) with metastatic triple-negative breast cancer (mTNBC)

被引：1
|
作者：
Brufsky, A. M. [1 ,2 ]
Bardia, A. [3 ]
Sedrak, M. S. [4 ]
Loibl, S. [5 ,6 ]
Tolaney, S. M. [7 ]
Punie, K. [8 ,9 ,10 ]
Hurvitz, S. A. [11 ]
Kalinsky, K. [12 ]
Cortes, J. [13 ]
O'Shaughnessy, J. [14 ]
Dieras, V. C. [15 ]
Piccart, M. [16 ]
Dasgupta, A. [17 ]
Kaushik, A. G. [17 ]
Lai, C. [18 ]
Shi, L. [19 ]
Rugo, H. S. [20 ]
机构：
[1] Univ Pittsburgh, Med Ctr, Magee Womens Hosp, Dept Hematol Oncol, Pittsburgh, PA USA
[2] Univ Pittsburgh, Med Ctr, Hillman Canc Ctr, Pittsburgh, PA USA
[3] UCLA Hlth Jonsson Comprehens Canc Ctr, Div Med Oncol, Los Angeles, CA USA
[4] Univ Calif Los Angeles, UCLA Hlth Jonsson Comprehens Canc Ctr, Canc & Aging Program, David Geffen Sch Med,Div Med Oncol, Los Angeles, CA USA
[5] German Breast Grp, Forsch, Neu Isenburg, Germany
[6] Ctr Haematol & Oncol Bethanien, Frankfurt, Germany
[7] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[8] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven Canc Inst, Leuven, Belgium
[9] Univ Hosp Leuven, Multidisciplinary Breast Ctr, Leuven Canc Inst, Leuven, Belgium
[10] Katholieke Univ Leuven, Dept Oncol, Expt Oncol Lab, Leuven, Belgium
[11] Fred Hutchinson Canc Ctr, Div Hematol & Oncol, Dept Med, UW Med,Clin Res Div, Seattle, WA USA
[12] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[13] Quironsalud Grp, Int Breast Canc Ctr, Barcelona, Spain
[14] Baylor Univ, Med Ctr, Texas Oncol, US Oncol, Dallas, TX USA
[15] UNICANCER, Ctr Eugene Marquis, Rennes, France
[16] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium
[17] Gilead Sci Inc, Dept Hlth Econ Outcomes Res, Foster City, CA USA
[18] Gilead Sci Inc, Dept Clin Dev, Foster City, CA USA
[19] Evidera Inc, Dept Patient Centered Res, Bethesda, MD USA
[20] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Med, San Francisco, CA USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.340
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
392P
引用
收藏
页码：S382 / S383
页数：2
相关论文
共 50 条
  • [1] Pharmacokinetics (PK) of sacituzumab govitecan (SG) in patients (Pts) with metastatic triple-negative breast cancer (mTNBC) and other solid tumors
    Sathe, A. G.
    Singh, I.
    Singh, P.
    Diderichsen, P.
    Wang, X.
    Chang, P.
    Phan, S-C.
    Girish, S.
    Othman, A. A.
    ANNALS OF ONCOLOGY, 2022, 33 : S214 - S214
  • [2] Exposure-response analyses of sacituzumab govitecan (SG) efficacy and safety in patients (pts) with metastatic triple-negative breast cancer (mTNBC).
    Singh, Indrajeet
    Sathe, Abhishek G.
    Singh, Pratap
    Diderichsen, Paul M.
    Fauchet, Floris
    Maringwa, John
    Pierrillas, Philippe
    Phan, See-Chun
    Girish, Sandhya
    Othman, Ahmed A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)
    Bardia, A.
    Tolaney, S. M.
    Loirat, D.
    Punie, K.
    Oliveira, M.
    Rugo, H. S.
    Brufsky, A.
    Kalinsky, K.
    Cortes, J.
    O'Shaughnessy, J.
    Dieras, V. C.
    Carey, L. A.
    Gianni, L.
    Piccart, M.
    Loibl, S.
    Goldenberg, D.
    Hong, Q.
    Olivo, M. S.
    Itri, L. M.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1149 - S1150
  • [4] Assessment of sacituzumab govitecan (SG) in Black patients (pts) from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC)
    Carey, Lisa A.
    Zelnak, Amelia
    Rugo, Hope S.
    Dalenc, Florence
    Nanda, Rita
    Danso, Michael
    Saghatchian, Mahasti
    Kalinsky, Kevin
    Firmin, Nelly
    Ruiz-Borrego, Manuel
    Favret, Anne
    Sun, Jun
    Schwartzberg, Lee
    Hilton, Christie
    Omene, Coral
    Young, Robyn
    Hurvitz, Sara A.
    Harting, Eliza
    Phan, See
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [5] Post-progression therapy outcomes in patients (pts) from the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
    Cortes, Javier
    Bardia, Aditya
    Loirat, Delphine
    Tolaney, Sara M.
    Punie, Kevin
    Oliveira, Mafalda
    Hurvitz, Sara A.
    Brufsky, Adam
    Sardesai, Sagar
    Kalinsky, Kevin M.
    Traina, Tiffany
    Hamilton, Erika
    O'Shaughnessy, Joyce
    Dieras, Veronique
    Carey, Lisa A.
    Piccart, Martine
    Loibl, Sibylle
    Rugo, Hope S.
    Zhu, Yanni
    Phan, See
    Gianni, Luca
    CANCER RESEARCH, 2022, 82 (04)
  • [6] Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
    Hegewisch-Becker, S.
    Oliveira, M.
    Traina, T.
    Tolaney, S. M.
    Loirat, D.
    Punie, K.
    Hurvitz, S. A.
    Lynce, F.
    Hamilton, E.
    Nanda, R.
    Hart, L.
    Richards, P.
    Malik, Z.
    Rugo, H. S.
    Dieras, V
    Bardia, A.
    Hong, Q.
    Phan, S.
    Itri, L. M.
    Loibl, S.
    Kalinsky, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 242 - 242
  • [7] Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).
    Kalinsky, Kevin
    Oliveira, Mafalda
    Traina, Tiffany A.
    Tolaney, Sara M.
    Loirat, Delphine
    Punie, Kevin
    Hurvitz, Sara A.
    Lynce, Filipa
    Hamilton, Erika P.
    Nanda, Rita
    Hart, Lowell L.
    Richards, Paul D.
    Malik, Zulfiqar A.
    Rugo, Hope S.
    Dieras, Veronique
    Bardia, Aditya
    Hong, Quan
    Olivo, Martin Sebastian
    Itri, Loretta
    Loibl, Sibylle
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study
    Weide, Rudolf
    Bardia, Aditya
    Tolaney, Sara
    Loirat, Delphine
    Punie, Kevin
    Oliveira, Mafalda
    Rugo, Hope
    Brufsky, Adam
    Kalinsky, Kevin
    Cortes, Javier
    O'shaughnessy, Joyce
    Dieras, Veronique
    Carey, Lisa
    Gianni, Luca
    Piccart-Gebhart, Martine
    Loibl, Sibylle
    Zhu, Yanni
    Phan, See-Chun
    Hurvitz, Sara
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 37 - 37
  • [9] Real-world outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) in 2L+in the United States (US)
    Kalinsky, Kevin
    Spring, Laura
    Yam, Clinton
    Taylor, Aliki
    Sjekloca, Nikoleta
    Kaushiva, Alpana
    Lai, Catherine
    Ntalla, Ioanna
    Nanda, Rita
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Assessment of sacituzumab govitecan (SG) in patients (pts) with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC)
    Hegewisch-Becker, S.
    Loirat, D. L.
    Punie, K.
    Bardia, A.
    Dieras, V
    Dalenc, F.
    Diamond, J. R.
    Fontaine, C.
    Wang, G.
    Rugo, H. S.
    Hurvitz, S. A.
    Kalinsky, K.
    O'Shaughnessy, J.
    Carey, L. A.
    Loibl, S.
    Gianni, L.
    Piccart, M.
    Hong, Q.
    Phan, S.
    Itri, L. M.
    Cortes, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 133 - 133
12345